Essential Pharma Acquires Renaissance Pharma Ltd with Its Clinical Stage Immunotherapy for the Treatment of Hhigh-risk Neuroblastoma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma portfolio and second product within rare disease Egham, UK – 9 April 2024 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have [...]